Publication | Open Access

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Hematological MalignancyMedicineHematologyClinical TrialsPathologyHigh-risk Myelodysplastic SyndromesMyeloid NeoplasiaPhase 2OncologyHealth Sciences